Search research articles
Contact Us
Filters
Showing results (451-460 of 467) with videos related to
Page
of 47
Sort By:
Scientific Reports
|
July 26, 2018
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
H Halse, A J Colebatch, P Petrone, et al.
The Journal of Clinical Investigation
|
February 7, 2017
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Paul A Beavis, Melissa A Henderson, Lauren Giuffrida, et al.
Nature Materials
|
April 4, 2018
Collapse of superconductivity in cuprates via ultrafast quenching of phase coherence
F Boschini, E H da Silva Neto, E Razzoli, et al.
Pathology
|
September 17, 2011
Mobilisation strategies for normal and malignant cells
L Bik To, Jean-Pierre Levesque, Kirsten E Herbert, et al.
BMJ Open
|
January 18, 2024
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials
Zoe McQuilten, Stephane Heritier, Lucy Fox, et al.
Leukemia
|
October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
British Journal of Haematology
|
December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia
David T Yeung, Andrew P Grigg, John Reynolds, et al.
Blood
|
September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P Hughes, Susan Branford, Deborah L White, et al.
Blood
|
December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T Yeung, Michael P Osborn, Deborah L White, et al.
Journal of the American College of Radiology : JACR
|
August 1, 2021
Factors Influential in the Selection of Radiology Residents in the Post-Step 1 World: A Discrete Choice Experiment
Charles M Maxfield, J Felipe Montano-Campos, Teresa Chapman, et al.
Page
of 47
Search research articles
Search
Showing results (451-460 of 467) with videos related to
Sort By:
Page
of 47
Scientific Reports
|
July 26, 2018
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
H Halse, A J Colebatch, P Petrone, et al.
The Journal of Clinical Investigation
|
February 7, 2017
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Paul A Beavis, Melissa A Henderson, Lauren Giuffrida, et al.
Nature Materials
|
April 4, 2018
Collapse of superconductivity in cuprates via ultrafast quenching of phase coherence
F Boschini, E H da Silva Neto, E Razzoli, et al.
Pathology
|
September 17, 2011
Mobilisation strategies for normal and malignant cells
L Bik To, Jean-Pierre Levesque, Kirsten E Herbert, et al.
BMJ Open
|
January 18, 2024
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials
Zoe McQuilten, Stephane Heritier, Lucy Fox, et al.
Leukemia
|
October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
British Journal of Haematology
|
December 23, 2025
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia
David T Yeung, Andrew P Grigg, John Reynolds, et al.
Blood
|
September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P Hughes, Susan Branford, Deborah L White, et al.
Blood
|
December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T Yeung, Michael P Osborn, Deborah L White, et al.
Journal of the American College of Radiology : JACR
|
August 1, 2021
Factors Influential in the Selection of Radiology Residents in the Post-Step 1 World: A Discrete Choice Experiment
Charles M Maxfield, J Felipe Montano-Campos, Teresa Chapman, et al.
Page
of 47